Literature DB >> 10788439

c-Jun and p53 activity is modulated by SUMO-1 modification.

S Muller1, M Berger, F Lehembre, J S Seeler, Y Haupt, A Dejean.   

Abstract

The ubiquitin-related SUMO-1 molecule has been shown recently to modify covalently a number of cellular proteins including IkappaBalpha. SUMO-1 modification was found to antagonize IkappaBalpha ubiquitination and protect it from degradation. Here we identify the transcription factors c-Jun and p53, two well known targets of ubiquitin, as new substrates for SUMO-1 both in vitro and in vivo. In contrast to ubiquitin, SUMO-1 preferentially targets a single lysine residue in c-Jun (Lys-229), and the abrogation of SUMO-1 modification does not compromise its ubiquitination. Activation of Jun NH(2)-terminal kinases, which induces a reduction in c-Jun ubiquitination, similarly decreases SUMO-1 modification. Accordingly, loss of the two major Jun NH(2)-terminal kinase phosphorylation sites in c-Jun, Ser-63 and Ser-73, greatly enhances conjugation by SUMO-1. A SUMO-1- deficient c-JunK229R mutant shows an increased transactivation potential on an AP-1-containing promoter compared with wild-type c-Jun, suggesting that SUMO-1 negatively regulates c-Jun activity. As with c-Jun, SUMO-1 modification of p53 is abrogated by phosphorylation but remains unaltered upon chemical damage to DNA or Mdm2-mediated ubiquitination. The SUMO-1 attachment site in p53 (Lys-386) resides within a region known to regulate the DNA binding activity of the protein. A p53 mutant, defective for SUMO-1 conjugation, shows unaltered ubiquitination but has a slightly impaired apoptotic activity, indicating that modification by SUMO-1 might be important for the full biological activity of p53. Taken together, these data provide a first link between the SUMO-1 conjugation pathway and the regulation of transcription factors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10788439     DOI: 10.1074/jbc.275.18.13321

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  121 in total

1.  Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity.

Authors:  Darja Schmidt; Stefan Müller
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

2.  Ubc9 interacts with a nuclear localization signal and mediates nuclear localization of the paired-like homeobox protein Vsx-1 independent of SUMO-1 modification.

Authors:  A L Kurtzman; N Schechter
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-01       Impact factor: 11.205

Review 3.  Modification with SUMO. A role in transcriptional regulation.

Authors:  Alexis Verger; José Perdomo; Merlin Crossley
Journal:  EMBO Rep       Date:  2003-02       Impact factor: 8.807

4.  PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases.

Authors:  Noora Kotaja; Ulla Karvonen; Olli A Jänne; Jorma J Palvimo
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

5.  SUMO modified proteins localize to the XY body of pachytene spermatocytes.

Authors:  Richard S Rogers; Amy Inselman; Mary Ann Handel; Michael J Matunis
Journal:  Chromosoma       Date:  2004-09-03       Impact factor: 4.316

6.  SUMO functions in constitutive transcription and during activation of inducible genes in yeast.

Authors:  Emanuel Rosonina; Sarah M Duncan; James L Manley
Journal:  Genes Dev       Date:  2010-05-26       Impact factor: 11.361

Review 7.  SUMO wrestling with type 1 diabetes.

Authors:  Manyu Li; Dehuang Guo; Carlos M Isales; Decio L Eizirik; Mark Atkinson; Jin-Xiong She; Cong-Yi Wang
Journal:  J Mol Med (Berl)       Date:  2005-04-02       Impact factor: 4.599

8.  Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation.

Authors:  Guillaume Bossis; Cécile E Malnou; Rosa Farras; Elisabetta Andermarcher; Robert Hipskind; Manuel Rodriguez; Darja Schmidt; Stefan Muller; Isabelle Jariel-Encontre; Marc Piechaczyk
Journal:  Mol Cell Biol       Date:  2005-08       Impact factor: 4.272

Review 9.  Ubiquitin and ubiquitin-like modifications of the p53 family.

Authors:  Ian R Watson; Meredith S Irwin
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

10.  Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression.

Authors:  Y Xu; J H Ahn; M Cheng; C M apRhys; C J Chiou; J Zong; M J Matunis; G S Hayward
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.